It proposes to expand the API manufacturing capacity from 21.9 TPM to 68.76 TPM
Dr Reddy's Laboratories is set to expand the capacity of three of its bulk drugs and intermediates manufacturing plants located in Telangana, with a combined investment of Rs 82 crore, according to reports.
Reportedly, the company has approached the Ministry of Environment and Forests for necessary approvals to expand the combined capacity of three facilities to over 142 tonnes per month from the existing 41 tonnes. This was listed in the minutes of the meeting held last month by the Expert Appraisal Committee (EAC) under MoEF.
It proposes to expand the API manufacturing capacity from 21.9 TPM to 68.76 TPM in an area of 16.81 acres (existing 13.27 acres and additional proposed 3.54 acres), EAC said.
"We have spent approx Rs 675 crore during the past three quarters in FY15. Full year FY15 plan may be around Rs 1,000 crore or so. FY16 numbers cannot be communicated at the moment," said the DRL official in a statement.
According to EAC, the manufacturing capacity for some of the fast moving drugs such as Omeprazole, Atorvastatin, Ciprofloxacin HCL, Fondaparinux Sodium, Metoprolol Succinate, Clopidogrel Bisulphate and Fexofenadine Hydrochloride are set to go up considerably once the expansion takes place.